[PDF] Top 20 Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo controlled, phase 3 clinical trials

... in patients with renal impairment may have clinical impli- ...of renal function in patients with gout; results reported here for pegloticase are consistent with these ... See full document

... in patients with renal impairment may have clinical impli- ...of renal function in patients with gout; results reported here for pegloticase are consistent with these ... See full document

... multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluat- ing Prevention of Progression in Chronic Kidney Disease [EPPIC-1 and ... See full document

... risedronate phase III studies and examined the safety and effect of the drug on kidney func- tion in osteoporosis patients (severe kidney impairment: creatinine clearance (CrCl) < 30 ... See full document

... This post-hoc analysis pooled data from 767 patients enrolled in two randomized, controlled, open-label trials of similar design comparing the treatment of iron deficiency ... See full document

... possible effect of IV iron on proteinuria, in a blinded, randomized, placebo-controlled cross-over study of eight patients with ND-CKD, Leehey et ...the effect of a single dose ... See full document

... the placebo group, and the efficacy was particularly high in the 120 μg group on the primary ...endpoint analysis, both TRK- 100STP groups showed improvements on each of the renal filtration ... See full document

... in patients with hyperuricaemia and ...of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled ... See full document

... cardiovascular clinical trials such as GREACE, CARE and TNT provide data on a significant number of subjects exposed to statins ...cardiac disease or who were at a high risk of cardiac ...test ... See full document

... and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group ...allopurinol-controlled, randomized, ... See full document

... Background: Chronic kidney disease (CKD) is a public health problem worldwide, and proteinuria is a well- established marker of disease progression in CKD ...antiproteinuric effect in ... See full document

... studies, patients were required to have pain for ≥14 days of each month for 3 months prior to study entry, with a mean pain severity ≥4 on daily pain diary ratings during the screening and baseline ... See full document

... Cognition is a complex term that includes various domains. Some studies have proposed relationships between specific exercise regimens and specific cognitive domains in chronic disease patients. ... See full document

... ≥ 2, ≥ 3, or ≥ 4 CVRFs was ...In clinical pharmacology studies using objective measures, las- miditan was associated with decreases in heart rate of − 5 to − 10 beats per minute following doses of 50 ... See full document

... 4 clinical trials of vilazodone, 5–8 a serotonin reuptake inhibitor and 5-HT 1A receptor partial agonist that is approved in the United States for the treatment of MDD in ...of patients who met ... See full document

... the analysis is that the very similar design and endpoints of the three primary studies ena- bled data to be pooled, providing a larger number of patients than in any individual study and enabling an ... See full document

... their clinical significance due to the use of a rather simple, not validated questionnaire, consistent effects on acute exacerbations were observed for both the reduced percentage of subjects experiencing at least ... See full document

... memantine analysis is that memantine use was not ...the effect of certain baseline characteristics was assessed, some unidentified characteristics of memantine patients, such as those accounting for ... See full document

... comparative, randomized, controlled studies exist to facilitate treatment ...of patients initially, but some patients subse- quently ...many patients and are chosen according to ... See full document

... included: patients with serum calcium levels above the upper limit of the normal range; severe hyperparathyroidism (parathyroid hormone [PTH] levels > 53 pmol/l (500 ng/l) [5]); serum phos- phate levels > ... See full document